Wird geladen...
Clinical strategies for acquired epidermal growth factor receptor tyrosine kinase inhibitor resistance in non-small-cell lung cancer patients
Epidermal growth factor receptor (EGFR) mutations (EGFRm(+)) occur in 10–35% of non-small-cell lung cancer (NSCLC) cases and confer sensitivity to EGFR tyrosine kinase inhibitors (TKIs). EGFR TKIs are standard treatments for NSCLC patients harboring EGFR exon 19 deletions or exon 21 L858R point muta...
Gespeichert in:
| Veröffentlicht in: | Oncotarget |
|---|---|
| Hauptverfasser: | , , |
| Format: | Artigo |
| Sprache: | Inglês |
| Veröffentlicht: |
Impact Journals LLC
2017
|
| Schlagworte: | |
| Online Zugang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5610029/ https://ncbi.nlm.nih.gov/pubmed/28969097 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.19925 |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|